2009-11-11 14:37:03 -
Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced President and Chief Executive Officer Abhay Joshi will present at the Lazard Capital Markets Sixth Annual Healthcare Conference at 11:30 a.m. ET on Wednesday, November 18. The conference will be held at The St. Regis Hotel in New York City.
About Alvine
Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine’s lead product candidate, ALV003, is being developed to treat patients with celiac disease. For additional information about the company, please visit www.alvinepharma.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
About Celiac Disease
Celiac disease
is the most common hereditary autoimmune disease with prevalence estimated to be as high as 1-2% in the U.S. and E.U.
Intestinal inflammation in celiac disease is triggered by the ingestion of gluten in genetically susceptible individuals. Gluten is a protein found naturally in wheat, rye, and barley, and is one of the most common and nutritionally significant ingredients in the human diet. Patients with celiac disease mount an immune response to gluten and gluten fragments, resulting in systemic immune-mediated damage in the gut and other organs. Gluten ingestion can be associated with symptoms such as nausea, diarrhea, constipation and rash. Complications of celiac disease can include osteoporosis, anemia, dermatitis, weight loss, diabetes, central nervous system conditions including depression, autoimmune diseases and malignancies. The only available option for individuals diagnosed with celiac disease today is a life-long adherence to a strict gluten-free diet, which is difficult to follow.
Alvine Pharmaceuticals, Inc.Kirk Essenmacher M.D., M.B.A.,
650-596-2434Vice President of Marketing, Corporate and Strategic
Development
